바이오테크 보도자료
-
- Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to
- Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, de...
- 2022년 07월 01일
-
- Quorum Software Announces Next Generation Planning and Economics Partnership with Schlumberger
- Quorum Software (Quorum), a global software leader dedicated to the energy industry, announced today that it has entered into an agreement with Schlumberger to jointly integrate Quorum’s industry-leading Pla...
- 2022년 07월 01일
-
- Medidata Announces Rapid Expansion of its Sensor Cloud Network with the Addition of 10 Health Technology Innovators
- Medidata, a Dassault Systèmes company, announced 10 highly innovative organizations have joined its groundbreaking Sensor Cloud Network. AliveCor, Aural Analytics, Biobeat, Blue Spark Technologies, Glooko, I...
- 2022년 07월 01일
-
- MRM Health Starts Clinical Trial with Next-Generation Optimized Consortium Therapeutic MH002 in Pouchitis
- MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency f...
- 2022년 06월 30일
-
- Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
- Takeda (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT...
- 2022년 06월 28일
-
- Asia Specific Biotechnology Instruments Market Is Poised To Exceed USD 40 Bn by 2032; R&D Arms of Major Multinational Pharmaceutical Corporations Fuels The Market: Report by Fact.MR
- The Biotechnology Instruments Market revenues were estimated at USD 46.1 Bn in 2021 and is anticipated to grow at a CAGR of 16.4% from 2022-2032, according to a recently published Fact.MR report. By the end ...
- 2022년 06월 22일
-
- Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis
- Galderma today announced the phase III OLYMPIA 2 trial met all primary and key secondary endpoints, showing nemolizumab as monotherapy significantly improved skin lesions and pruritus (itch) compared with pl...
- 2022년 06월 22일
-
- Waters and BioInfra Establish the ASEAN Academy for Bioanalysis to Promote Analytical Skills Development
- Waters Corporation (NYSE:WAT) announced a collaboration with BioInfra, a pioneering contract research organization (CRO) company for the pharmaceutical and clinical fields, to jointly establish the ASEAN Aca...
- 2022년 06월 21일
-
- Companies in the Global Omics Based Clinical Trials Market Expedite Product Innovations to Stay at Forefront; Expected Sales to Reach USD 61.7 Bn By 2032: Fact.MR’s Study
- The Omics Based Clinical Trials Market revenues were estimated at USD 26.2 Bn in 2021 and is anticipated to grow at a CAGR of 8.1% from 2022 to 2032, according to a recently published Fact.MR report. By the ...
- 2022년 06월 21일
-
- AOP Health Presents Final Results From Its CONTINUATION-PV Study - up to 7.5 Years Treatment With BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients - at EHA 2022 Annual Meeting
- AOP Health announced the final results on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from its CONTINUATION-PV study in an oral presentation at the prestigious EHA (European Hematology A...
- 2022년 06월 21일
전시회
